Halozyme Therapeutics, Inc. (HALO)

NMS – Real Time Price. Currency in USD

101.29

-1.33 (-1.30%)

Market open: Aug 12, 2026, 10:45 AM EDT

104.19

+1.57 (1.53%)

Previous after-hours: Aug 11, 2026, 7:36 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

1.40B

1.02B

829M

660M

Cost of goods sold

-305M

-230M

-266M

-182M

Gross Profit

1.09B

785M

563M

478M

Operating expenses (excl. COGS)

-275M

-233M

-226M

-188M

Operating Income

816M

551M

338M

289M

Non-operating income, total

-349M

11M

-41M

Pretax income

467M

557M

348M

249M

Equity in earnings

Taxes

-150M

-113M

-67M

-47M

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

317M

444M

282M

202M

Discontinued operations

Net income

317M

444M

282M

202M

Dilution adjustment

Preferred dividends

Halozyme Therapeutics, Inc. (HALO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Halozyme Therapeutics, Inc. (HALO)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Halozyme Therapeutics, Inc. (HALO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Halozyme Therapeutics, Inc. (HALO)

Income Statement (Annual)

Income Statement (Annual)